Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03778957 · ClinicalTrials.gov registry record · Phase 3
A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma
A Phase 3 study of Hepatocellular Carcinoma, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 724
- Enrollment target
- 20
- Study locations
NCT03778957 is a Phase 3 study of Hepatocellular Carcinoma that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 724 participants, above the 252-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (187% higher). The trial reports 20 study locations across 17 states.
The verdict
NCT03778957, a Phase 3 study of Hepatocellular Carcinoma, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 724 participants
- Enrollment target
- 20
- Study locations
Study Summary
A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab and bevacizumab therapy in patients with locoregional hepatocellular carcinoma
Conditions Studied
Interventions
- DRUG Bevacizumab
- OTHER Placebo
- DRUG Durvalumab
- PROCEDURE Transarterial Chemoembolization (TACE)
Study Locations (20)
California
- Research Site - Costa Mesa
- Research Site - La Jolla
- Research Site - Orange
Florida
- Research Site - Jacksonville
- Research Site - Miami
District of Columbia
- Research Site - Washington D.C.
Hawaii
- Research Site - Honolulu
Illinois
- Research Site - Chicago
Louisiana
- Research Site - Shreveport
Michigan
- Research Site - Detroit
Minnesota
- Research Site - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 724 participants |
| Start Date | 2018-11-30 |
| Est. Completion | 2026-08-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03778957
The ClinicalTrials.gov registry entry for NCT03778957 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 724 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 252-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (187% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Bevacizumab is the first listed.
NCT03778957 reports 20 study locations spanning 17 distinct geographic areas - top geographies include California, Florida, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT03778957 about?
NCT03778957 is a clinical study titled "A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma". A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab and bevacizumab therapy in patients with locoregional hepatocellular carcinoma
What is the current status of trial NCT03778957?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 724 participants. The study started on 2018-11-30. Estimated completion is 2026-08-31.
What conditions does trial NCT03778957 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma.
What interventions are being tested in trial NCT03778957?
The interventions under investigation include: Bevacizumab (DRUG), Placebo (OTHER), Durvalumab (DRUG), Transarterial Chemoembolization (TACE) (PROCEDURE).
Who is sponsoring clinical trial NCT03778957?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03778957 being conducted?
This trial has 20 study locations across California, District of Columbia, Florida, Hawaii, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
RECRUITING · Phase 3
-
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
RECRUITING · Phase 3
-
Evaluating Novel Therapies in ctDNA Positive GI Cancers
RECRUITING · Phase 3
-
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
ACTIVE NOT RECRUITING · Phase 3
-
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.